MedTrace Logo

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

NCT03019536 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-10-10

Study results available
· View outcomes & findings →

Summary

The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body. This study will last up to 65 weeks, not including screening. Screening is required within 90 days prior to the start of the study.

Conditions

  • Alzheimer Disease

Interventions

DRUG

LY3303560 - IV

Administered IV

DRUG

Placebo - IV

Administered IV

DRUG

Florbetapir F 18

Administered IV during the Positron Emission Tomography (PET) scan performed during screening.

DRUG

Flortaucipir F18

Administered IV during the PET scan performed during the study.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-06-05
Completion
2019-06-05
FDA Drug
Yes

Countries

  • United States
  • Japan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019536 on ClinicalTrials.gov